144
edits
mNo edit summary |
|||
(4 intermediate revisions by 2 users not shown) | |||
Line 145: | Line 145: | ||
450-459 (in males) | 450-459 (in males) | ||
>480 during | >480 during X-ECG | ||
X-ECG | |||
|valign="top"|3 | |valign="top"|3 | ||
Line 189: | Line 187: | ||
|0.5 | |0.5 | ||
|- | |- | ||
|colspan="4"|''Total score | |colspan="4"|''Total score ≤1 Low probability; 1.5-3 Intermediate probability; ≥3.5 High probability'' | ||
|} | |} | ||
Diagnostic criteria by Schwartz et al. (2011)<cite>Schwartz2001</cite> | |||
==Clinical diagnosis== | ==Clinical diagnosis== | ||
Line 310: | Line 309: | ||
===Medication/Other therapies:=== | ===Medication/Other therapies:=== | ||
*Beta-blockers are the cornerstone of therapy in LQTS. Beta-blockers even reduce the risk of sudden death in patients in whom a genetic defect has been found, but no QT | *Beta-blockers are the cornerstone of therapy in LQTS. Beta-blockers even reduce the risk of sudden death in patients in whom a genetic defect has been found, but no QT prolon | ||
Line 318: | Line 315: | ||
<biblio> | <biblio> | ||
#Schwartz2001 pmid=11136691 | #Schwartz2001 pmid=11136691 | ||
#Alders pmid=20301308 | |||
#adenosine pmid=16105845 | |||
#priori pmid=12736279 | #priori pmid=12736279 | ||
#Adler pmid=22300664 | #Adler pmid=22300664 | ||
# | #Shimizu2009 pmid=19926013 | ||
# | #Moss pmid=17470695 | ||
#Sy pmid=22042885 | |||
#Schwartz2011 pmid=22083145 | |||
#Viskin pmid=20116193 | |||
#Shimizu2004 pmid=15851169 | |||
</biblio> | </biblio> |